MR based lipoprotein analysis for patients with advanced hypercholesterolemia or Lp(a)-hypercholesterolemia undergoing chronic lipoprotein apheresis or PCSK9-inhibitor therapy

• Conditions: E78.0; E78.5; Pure hypercholesterolaemia; Hyperlipidaemia, unspecified

• Registration Number: DRKS00012721
• Lead Sponsor: Benefit for Research on Arterial Hypertension, Dyslipidemia and Vascular Risk and Education - BRAVE e.V.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-08-09
• Study Completion: 2017-12-21
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 104

Inclusion Criteria

Patients suffering from severe hypercholesterolemia and/ or hyper-Lp(a)-emia will be included.

Exclusion Criteria

no specific exclusion criteria

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change of particel size in different lipid fractions undergoing different therapies like statins, PCSK9-I, lipoproteinapheresis; measured by nuclear magnetic resonance (NMR).<br>All drugs are approved by Federal Institute for Drugs and Medical Devices (BfArM) and are not subjects to special conditions.

Secondary Outcome Measures

Name	Time	Method
Prevention of a progress of coronary heart disease (CHD), cerebor vascular disease (CVD), peripheral arterial disease (PAD). The medical history will be recoreded with respect to changes of the vascular status.